T. N. Trushnikova

We don’t have enough information about this author to calculate their statistics. If you think this is an error let us know.
Learn More
Disease-modifying drugs (DMD) are currently used in the treatment of patients with multiple sclerosis (MS) in accordance with therapeutic standards, with the aim of decreasing the risk of developing exacerbations and thus reducing the rate of development of disability. However, the use of first-line substances is not successful in all cases. Second-line(More)
The expression of semaphorin CD100 by intact peripheral blood T lymphocytes from patients with multiple sclerosis (MS) not receiving immunomodulatory treatment was studied. Cellular CD100 expression levels were assessed, along with levels of CD72 receptor-carrying B lymphocytes. Significant differences were seen between the levels of CD100 expression in(More)
Objective. To study serum concentrations of BDNF and CNTF in patients with multiple sclerosis (MS) and compare them to clinical characteristics of MS. Material and methods. We examined 43 patients with confirmed diagnosis of MS according to McDonald's criteria with remitting type of disease course. Patients were in a stable condition and did not receive(More)
For a study of the serotonergic mechanisms of a fatigue syndrome, we examined 60 patients with remitting and secondary progressive multiple sclerosis and 12 healthy persons. The serotonin content in the platelets of the peripheral blood was measured using an immunoenzymatic assay. Signs of the fatigue syndrome were evaluated according to the FSS scale. In(More)
  • 1